AGRANULOCYTOSIS ASSOCIATED WITH NOVOBIOCIN ADMINISTRATION: REPORT OF A CASE
Authors: H J SIMON, D E ROGERS
Journal: Annals of Internal Medicine (1957)

Case Reports1 April 1957AGRANULOCYTOSIS ASSOCIATED WITH NOVOBIOCIN ADMINISTRATION: REPORT OF A CASEHAROLD J. SIMON, M.D., DAVID E. ROGERS, M.D.HAROLD J. SIMON, M.D.Search for more papers by this author, DAVID E. ROGERS, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-46-4-778 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptNovobiocin,† a new antibiotic agent with antimicrobial activity against a number of gram-positive and selected gram-negative microörganisms, has recently been subjected to laboratory and clinical trials by a number of investigators.1, 2 Studies by Welch and Wright have indicated that Streptonivicin, Cathomycin and Cardelomycin are the identical antibiotic substance now generically labeled novobiocin.3The present note records the appearance of agranulocytosis in a patient receiving novobiocin for a proteus osteomyelitis of the hip.CASE REPORTA 55 year old white married salesman was admitted to The New York Hospital on July 8, 1956, because of pain in his right hip...Bibliography1. Clinical and laboratory evaluation of novobiocin, Antibiotic Med. 2: 201-290 (Apr.) 1956. Google Scholar2. RutenburgShapiroSchweinberg AMPF: Novobiocin in the treatment of surgical infections due to staphylococci and other gram-positive bacteria, New England J. Med. 255: 325-330 (Aug. 16) 1956. CrossrefMedlineGoogle Scholar3. WelchWright HWW: The common identity of Cathomycin and Streptonivicin, Antibiotics and Chemotherapy 5: 670, 1956. Google Scholar4. DaussetNennaBrecy JAH: Leukoagglutinins. V. Leukoagglutinins in chronic idiopathic or symptomatic pancytopenia and in paroxysmal nocturnal hemoglobinuria, Blood 9: 696 (July) 1954. CrossrefMedlineGoogle Scholar5. Hunter D: Industrial toxicology, Quart. J. Med. 12: 185, 1943. Google Scholar6. CahanMeilmanJacobsen AMEBM: Agranulocytosis following Pyribenzamine (tripelennamine): report of a case, New England J. Med. 241: 865-867 (Dec. 1) 1949. CrossrefMedlineGoogle Scholar7. Hilker AW: Agranulocytosis from tripelennamine (Pyribenzamine) hydrochloride, J. A. M. A. 143: 741-742 (June 24) 1950. CrossrefMedlineGoogle Scholar8. MartlandGuck HSJK: Agranulocytosis after antihistamine therapy, J. A. M. A. 143: 742-743 (June 24) 1950. CrossrefMedlineGoogle Scholar9. WelchLewisPutnamRandall HCNLEWA: A study of the sensitizing potential of novobiocin, Antibiotic Med. 3: 27-32 (June) 1956. MedlineGoogle Scholar10. DavidBurgner NAPR: Clinical effectiveness and safety of novobiocin, Antibiotic Med. 2: 219-229 (Apr.) 1956. MedlineGoogle Scholar11. NicholsFinland RLM: Novobiocin; a limited bacteriologic and clinical study of its use in forty-five patients, Antibiotic Med. 2: 241-257 (Apr.) 1956. MedlineGoogle Scholar12. MartinHeilmanNicholsWellmanGeraci WJFRDRWEJE: Novobiocin: further observations, Antibiotic Med. 2: 258-267 (Apr.) 1956. MedlineGoogle Scholar13. HoeksemaCaronHinman HELJW: Novobiocin. III. The structure of novobiocin, J. Am. Chem. Soc. 78: 2019 (May 5) 1956. CrossrefGoogle Scholar14. KrackeParker RRFP: The etiology of granulopenia (agranulocytosis), J. Lab. and Clin. Med. 19: 799-818 (May) 1934. Google Scholar15. Vaughan SL: Drug-induced blood dyscrasias, New York State J. Med. 55: 2457-2462 (Sept. 1) 1955. MedlineGoogle Scholar16. ReznikoffWells PM: Toxic effects of therapeutic agents upon the hemopoietic system, Tr. New York Acad. Sc. 18: 233-242 (Jan.) 1956. CrossrefMedlineGoogle Scholar17. Personal communications from Dr. James Dugger, The Upjohn Company, Kalamazoo, Michigan. Google Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: New York, N. Y.*Received for publication November 15, 1956.From the Department of Medicine, The New York Hospital-Cornell University Medical Center.Requests for reprints should be addressed to David E. Rogers, M.D., Department of Medicine, The New York Hospital, 525 East 68th Street, New York 21, N. Y.†Novobiocin is marketed under the trade names of Albamycin (Upjohn Company) and Cathomycin (Merck and Company, Incorporated). PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byA New-Class Antibacterial—Almost. Lessons in Drug Discovery and Development: A Critical Analysis of More than 50 Years of Effort toward ATPase Inhibitors of DNA Gyrase and Topoisomerase IVAgranulocytosis during antibiotic therapy: Drug sensitivity or sepsis?Disorders of Leukocytes Leading to Recurrent Infection 1 April 1957Volume 46, Issue 4Page: 778-784KeywordsAdverse reactionsAntibioticsAntimicrobialsClinical laboratoriesClinical trialsHipOsteomyelitisResearch laboratories ePublished: 1 December 2008 Issue Published: 1 April 1957 PDF downloadLoading ...